Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20278339 | 0.84 | TAAR1 (0.49) | IDO1AGXTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL17241276 | 0.82 | IDO1 (0.49) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL5761123 | 0.78 | IDO1 (0.47) | IDO1AGXTMAOBTAAR1PPARG | |
| SCHEMBL2197431 | 0.76 | IDO1 (0.46) | IDO1AGXTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6311891 | 0.76 | TAAR1 (0.64) | IDO1AGXTMAOBTAAR1SIGMAR1 | |
| SCHEMBL13516238 | 0.76 | PPARA (0.42) | IDO1TAAR1SIGMAR1PPARGPPARA | |
| SCHEMBL30138659 | 0.76 | SIGMAR1 (0.53) | IDO1AGXTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1513595 | 0.76 | SIGMAR1 (0.53) | IDO1AGXTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3133598 | 0.76 | TAAR1 (0.54) | IDO1AGXTCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL113325 | 0.76 | TAAR1 (0.48) | CYP2D6TAAR1SIGMAR1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-18 | — | — | US | disclosed |
| WO-2023205458-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-114507202-B | Phellinin compound and preparation method and application thereof | 海南大学 | 2023-10-03 | — | — | CN | disclosed |
| CN-114507202-A | Morusin compound and preparation method and application thereof | 海南大学 | 2022-05-17 | — | — | CN | disclosed |
| CN-114008025-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| EP-1879896-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | ACHE, BCHE, DDT | IDO1 596/4885AGXT 323/4885CYP1A2 1974/4885 |
| US-20080153828-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | IDO1 890/4885AGXT 3471/4885CYP1A2 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.